DMRA
insider transactionsDamora Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-955
0 buy · 955 sell
Net value · 365d
-$20.4K
$0 in · $20.4K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 955 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Jennifer Jarrett KEY
President and Chief Executive…
$0
1.5M sh
Own New
-
Grant·A
Jennifer Jarrett KEY
President and Chief Executive…
$0
500.0K sh
Own New
-
Grant·A
General Counsel
$0
250.0K sh
Own New
-
Grant·A
Director
$0
37.3K sh
Own New
-
Grant·A
Director
$0
37.3K sh
Own New
-
Grant·A
Director, 10% Owner
$0
37.3K sh
Own New
-
Grant·A
Director
$0
37.3K sh
Own New
-
Exercise·M
Director
$0
129 sh
Own New
-
Exercise·M
Director
$0
129.0K sh
Own +1606%
-
Grant·A
Chief Medical Officer
$0
528.6K sh
Own New
-
Grant·A
Chief Medical Officer
$0
264.6K sh
Own New
-
Grant·A
Chief Operating Officer
$0
444.2K sh
Own New
-
Grant·A
Chief Operating Officer
$0
190.4K sh
Own New
-
Exercise·M
Hans T. Schambye KEY
Chief Executive Officer
$0
1.4K sh
Own +106%
-
Sell·S
Hans T. Schambye KEY
Chief Executive Officer
$15.0K
700 sh · $21.38
Own -13%
-
Exercise·M
Hans T. Schambye KEY
Chief Executive Officer
—
1.4K sh
Own +34%
-
Exercise·M
General Counsel
$0
680 sh
Own +106%
-
Sell·S
General Counsel
$5.5K
255 sh · $21.38
Own -12%
-
Exercise·M
General Counsel
—
680 sh
Own +48%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 30, 2026 | Jennifer Jarrett KEY | Grant A | 1.5M | $0 |
| Mar 30, 2026 | Jennifer Jarrett KEY | Grant A | 500.0K | $0 |
| Mar 23, 2026 | Garrett Winslow | Grant A | 250.0K | $0 |
| Mar 23, 2026 | Cameron Turtle | Grant A | 37.3K | $0 |
| Mar 23, 2026 | Michael Landsittel | Grant A | 37.3K | $0 |
| Mar 23, 2026 | Fairmount Funds Management LLC / Fairmount Healthcare Fund II L.P. / Fairmount Healthcare Co-Invest V L.P. / Tomas Kiselak / Peter Evan Harwin | Grant A | 37.3K | $0 |
| Mar 23, 2026 | Julianne Bruno | Grant A | 37.3K | $0 |
| Feb 9, 2026 | Julianne Bruno | Exercise M | 129 | $0 |
| Feb 9, 2026 | Julianne Bruno | Exercise M | 129.0K | $0 |
| Jan 5, 2026 | Becker L. Hewes | Grant A | 528.6K | $0 |
| Jan 5, 2026 | Becker L. Hewes | Grant A | 264.6K | $0 |
| Jan 5, 2026 | Sherwin Sattarzadeh | Grant A | 444.2K | $0 |
| Jan 5, 2026 | Sherwin Sattarzadeh | Grant A | 190.4K | $0 |
| Jan 2, 2026 | Hans T. Schambye KEY | Exercise M | 1.4K | $0 |
| Jan 2, 2026 | Hans T. Schambye KEY | Sell S | 700 | $15.0K |
| Jan 2, 2026 | Hans T. Schambye KEY | Exercise M | 1.4K | — |
| Jan 2, 2026 | Garrett Winslow | Exercise M | 680 | $0 |
| Jan 2, 2026 | Garrett Winslow | Sell S | 255 | $5.5K |
| Jan 2, 2026 | Garrett Winslow | Exercise M | 680 | — |
About DMRA insider trading
This page tracks insider transactions for Damora Therapeutics, Inc. (DMRA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.